Skip to main content
main-content

11.10.2016 | Case Report | Ausgabe 5/2017

International Ophthalmology 5/2017

Alemtuzumab-induced remission of multiple sclerosis-associated uveitis

Zeitschrift:
International Ophthalmology > Ausgabe 5/2017
Autoren:
Mark D. Willis, Trevor P. Pickersgill, Neil P. Robertson, Richard W. J. Lee, Andrew D. Dick, Ester Carreño

Abstract

Purpose

The purpose of the study was to report a case of multiple sclerosis (MS)-associated uveitis refractory to conventional immunosuppressants, with subsequent remission following treatment with alemtuzumab.

Methods

Case report Patient was treated with intravenous alemtuzumab, a lymphocyte depleting anti-CD52 monoclonal antibody that has recently been approved for use in relapsing MS.

Results

A 17-year-old female presented with bilateral optic neuritis and subsequently bilateral intermediate uveitis and secondary macular oedema. She was diagnosed with active relapsing MS for which she received treatment with alemtuzumab. The intraocular inflammation previously refractory to conventional immunosuppressants responded to alemtuzumab, inducing remission.

Conclusions

To our knowledge, this is the first such report of alemtuzumab treatment in MS-associated ocular inflammatory disease and may demonstrate a potential utility for this drug in related conditions.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

★ PREMIUM-INHALT
e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Premium-Inhalten der Fachzeitschriften, inklusive eines Print-Abos.

Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 5/2017

International Ophthalmology 5/2017Zur Ausgabe

Neu im Fachgebiet Augenheilkunde

15.06.2018 | Video plus | Ausgabe 7/2018

Diakaustische Kammerwinkeluntersuchung

Videobeitrag

01.06.2018 | themenschwerpunkt | Ausgabe 3/2018

Das Kind in der Kunst

22.05.2018 | Das Frühgeborene | Leitthema | Ausgabe 6/2018

Frühgeborenenretinopathie in welchem Stadium wie behandeln?

Aktueller Wissensstand und Ausblick